Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple Pathways

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Triple-negative breast cancer (TNBC) remains a significant therapeutic challenge due to limited targeted treatment options.
• Novel small molecules with potent anti-cancer activity are urgently needed to address unmet clinical needs.

Purpose of the Study:

• To identify and characterize a novel pyrazole-based derivative, P3C, for its anti-cancer potential.
• To elucidate the molecular mechanisms underlying P3C's cytotoxicity, especially in TNBC.

Main Methods:

• Cytotoxicity assays against a panel of 27 human cancer cell lines.
• In vitro mechanistic studies including ROS generation, mitochondrial membrane potential, caspase activation, cell cycle analysis, and Western blotting.
• Transcriptome analysis of P3C-treated TNBC cell lines.

Main Results:

• P3C demonstrated potent cytotoxicity against multiple cancer cell lines, with notable efficacy in TNBC cell lines (0.25-0.49 µM).
• P3C induced apoptosis via both intrinsic and extrinsic pathways, evidenced by ROS accumulation, mitochondrial depolarization, and caspase activation.
• P3C disrupted microtubules, induced DNA fragmentation, arrested the cell cycle, and modulated key signaling pathways (e.g., MAPK, STAT3, CREB, NF-kB) in TNBC cells.
• Transcriptome analysis confirmed P3C's impact on apoptosis, oxidative stress, kinase activity, and microtubule stability.

Conclusions:

• P3C is a promising novel anti-cancer agent with significant cytotoxic effects on TNBC.
• P3C exerts its anti-cancer effects through multifaceted mechanisms, including induction of apoptosis, oxidative stress, and disruption of microtubule dynamics.
• Further investigation of P3C as a potential therapeutic candidate for TNBC is warranted.